Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
One prescription, multiple diseases, and a cascade of transformative outcomes for the industry
REDEFINE Clinical Trial Program Overview The REDEFINE program is a comprehensive Phase 3 clinical trial initiative evaluating CagriSema across diverse populations and settings: Expected Completion: The REDEFINE program is anticipated to complete enrollment and report results between 2024-2026, providing comprehensive data to support regulatory submissions worldwide
Retatrutide (research code LY-3437943) is a synthetic 39-amino-acid peptide developed by Eli Lilly as a novel triple agonist of the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIP-R), and glucagon receptor (GCG-R)
Important Contraindications and Warnings Certain individuals should not take Wegovy pills
But you can switch from one medicine to the other, says Pessah-Pollack
